High Expression Level of ROR1 and ROR1-signaling Associates With Venetoclax Resistance In Chronic Lymphocytic Leukemia

We examined the CLL cells transcriptome data of six patients who fail to clear their leukemia cells and develop progressive disease on venetoclax therapy. Methods: CLL cells were collected prior to venetoclax therapy (Sample Collection 1 (SC1)) and then more than 1 year later (Sample Collection 2 (SC2)). Negative isolation of CLL cells to ≥95% purity was performed prior to RNA isolation. Transcriptome profiles of CLL cells prior to venetoclax therapy and more than 1 year later on venetoclax

本研究对6例接受维奈克拉（venetoclax）治疗后无法清除白血病细胞且出现病情进展的慢性淋巴细胞白血病（Chronic Lymphocytic Leukemia, CLL）患者的CLL细胞转录组数据进行了分析。方法：在维奈克拉治疗前（样本收集1（SC1））以及治疗超过1年后（样本收集2（SC2））分别采集CLL细胞。在进行RNA提取前，通过阴性分选法将CLL细胞的纯度提升至≥95%。针对维奈克拉治疗前以及接受维奈克拉治疗超过1年后的CLL细胞，完成了转录组谱分析。